Last reviewed · How we verify
BRIGATINIB
At a glance
| Generic name | BRIGATINIB |
|---|---|
| Drug class | Kinase Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2017 |
Approved indications
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Constipation
- Stomatitis
- Dyspepsia
- Rash
- Pruritus
- Cough
- Dyspnea
- ILD/Pneumonitis
Key clinical trials
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (PHASE2)
- Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
- Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping (PHASE2)
- A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
- Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (PHASE2)
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (PHASE2)
- A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
- Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRIGATINIB CI brief — competitive landscape report
- BRIGATINIB updates RSS · CI watch RSS